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Abstract: Cystic fibrosis (CF) is a progressive life threatening multisystem genetic disease which affects
the CF transmembrane conductance regulator channel. Respiratory causes remain the most common
mortality in CF. With the onset of newborn screening, initiating treatments both for prophylaxis and
disease management, optimizing nutritional support, and developing therapies targeting CF transmembrane
conductance regulator protein, this has significantly changed the face of managing this devastating disease.
Bronchoscopy and related procedures such as bronchoalveolar lavage (BAL), transbronchial biopsies, and
protected brush sampling have been looked at in the management of CF as patients with CF continue to
live longer with the help of newer therapies, the microbiome in the lung becomes less diverse along with
increased occurrences for noninfectious causes of airway diseases. Though bronchoscopy has been used in
conjunction with other modalities such as computed tomography and sputum induction providing a better
understanding of the progression of the disease, it still remains valuable in the diagnosis and management of CF.
Keywords: Bronchoscopy; microbiology; airway diseases; progression of disease
Submitted May 05, 2017. Accepted for publication Jun 21, 2017.
doi: 10.21037/jtd.2017.06.143
View this article at: http://dx.doi.org/10.21037/jtd.2017.06.143

Introduction
Cystic fibrosis (CF) is an autosomal recessive disease
causing mutational defects of the CF transmembrane
conductance regulator (CFTR) protein leading to multi
organ involvement such as bronchiectasis, chronic sinusitis,
pancreatic insufficiency, hepatobiliary disease, CF related
diabetes, and osteoporosis. This gene is located on the long
arm of chromosome 7. The median predicted survival of
CF patients is 41.6 years based on the CF patient registry
in 2015 (1). The mutation in the CFTR protein causes
dysregulation of the chloride movement through the
channel resulting in the production of thick, viscous mucus
in the regions with the most CFTR expression (2). This
buildup of thick mucus causes obstruction and inflammation
leading to defective mucociliary clearance, chronic infection,
and eventually organ failure (3).
Progressive respiratory disease remains the leading cause
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of morbidity and mortality in CF (2). The vicious cycle of
mucus plugging, vigorous neutrophilic inflammation with
the release of interleukin (IL)-8 neutrophil elastase have
led to bronchiectasis by causing destruction of the airway
tissue (4). With the profound neutrophilic inflammation,
there is a release of deoxyribonucleic acid (DNA) that is
broken down in the infected mucus increasing the viscosity
of the secretions (5). Over time with small and medium
airway obstruction and recurrent infections, the lung
parenchyma undergoes atelectasis, collapse and pneumonia.
The bronchial arterial circulation undergoes dilatation and
neovascularity likely due to vascular endothelial growth
factors in response to inflammation along with anastomotic
changes at the capillary level (6). Several studies have
looked into the various microbiological communities in
CF with particular focus on certain organisms that are
pathognomonic for CF such as Haemophilus influenza,
Staphylococcus aureus, Pseudomonas aeruginosa, and
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Table 1 CFTR class mutations
Class

Defect

Example

Class I

Defect in protein expression causing premature stop mutation

Nonsense mutations G542X

Class II

Defect in processing and maturation

delF508 (most common)

Class III

Defect in regulation causing problems in activation and gating

G551D

Class IV

Defect in chloride conductance though the channel is activated

R117H, R347P

Class V

Decrease in amount of functioning protein

3849 + 10 kb C →T

Burkholderia cepacia complex (7).
CFTR dysfunction is based on the mutations initiating at
the level of protein translation with the loss or incomplete
protein expression to conducting defects. The mutations are
classified from I to V. Table 1 depicts the type of mutation
and examples of mutations in the specific class. Some
mutations may have features of more than one class. By
understanding the different types of mutations, this helps
to understand the disease presentation and design newer
therapies specific for each mutation class (2).
Management of CF lung disease includes airway
clearance with beta agonist bronchodilators, mucolytic
agents such as inhaled dornase alpha and hypertonic saline,
inhaled antibiotics such as tobramycin, aztreonam, and
colistimethate in combination with chest physiotherapy
and other percussive and oscillatory devices (3).
CFTR modulators improve the function of the dysfunctional
CFTR protein based on the mutation. Two such drugs that
are used are Ivacaftor specific for gating mutations such
as G551D mutation and defect in chloride conductance
R117H and Lumacaftor-Ivacaftor for homozygous
F508del mutation which is involved with CFTR protein
trafficking and folding and channel gating. Studies have
shown improvement in lung function and quality of life (3).
Microbiome in CF
The microbiology in the CF lung has a distinctive presentation
over a period of time. Most often in the younger population,
Staphylococcus aureus and Haemophilus influenza
(nontypeable) followed by Pseudomonas aeruginosa.
Different strains of Pseudomonas aeruginosa have been
identified in several regions of the respiratory system (8,9).
Other pathogens that are seen in the advance stage of CF
include Burkholderia cepacia complex, Stenotrophomonas
maltophilia, and fungi such as Aspergillus fumigatus
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and Scedosporium apiospermum. Non-tuberculous
mycobacteria (NTM) are increasingly prevalent in CF
with the most frequently identified species include
Mycobacterium avium complex and Mycobacterium
abscessus (10).
Sputum cultures obtained quarterly from CF patients may
not reveal the extensive microbiota in the airway as there
are regional differences and diversity of the microbiota.
However sputum cultures remain useful in monitoring
most of the pathogens in connection with exacerbations (7).
It has been established that the microbiome diversity
decreases in advanced lung disease and in older CF patients
whereas the microbiome in the younger CF patients have a
higher diversity. This is likely due to use of antibiotics due
to recurrent pulmonary exacerbations and the progressive
decline in FEV1. It has also been suggested that pulmonary
exacerbations may be due to spread of infection from other
areas of affected airways to the unaffected airways instead of
increased burden of the microbiome.
The microbiome identified in the lower airways is distinct
from upper airway microbiome (11). Studies have shown
various stages of disease in different regions of CF lungs
as well as several pathogens distributed disproportionately
throughout the lung (11,12). Combination of culture
based studies and culture independent molecular studies
have shown increased diversity and increased prevalence
of anaerobic bacteria. With the increasing identification of
uncommon bacteria, its relation to pulmonary exacerbations
and decline in FEV1 still remains in question.
Table 2 demonstrates the most common pathogens seen in CF.
Utility of bronchoscopy in diagnosis and culture
guided therapy in CF
Studies have shown sputum obtained from stable non CF
bronchiectasis individuals may be useful as inexpensive and
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Table 2 Different organisms seen in cystic fibrosis
Bacteria
Staphylococcus aureus
Pseudomonas aeruginosa
Burkholderia cepacia
Stenotrophomonas maltophilia
Achromobacter xylosoxidans
Haemophilus influenzae
Prevotella
Fungi
Aspergillus fumigatus
Candida albicans
Scedosporium
Mycobacteria
Mycobacterium avium complex
Mycobacterium abscessus
Mycobacterium chelonae

least invasive method to evaluate airway colonization of
pathogens. However, not all individuals with bronchiectasis
demonstrate the pathogenic microbiota in the lower
airways with standard sputum collection. Induced sputum
has been shown a preferred technique in evaluating airway
colonization of pathogens (13).
In CF, expectorated sputum is useful for identifying
pathogens for the management of pulmonary disease
especially in individuals who are able to expectorate. In
those who are not able to expectorate or have mild disease,
sputum induction with nebulized 3 percent saline has been
effective in measuring the inflammatory state which is
comparable to expectorated samples (14). Bronchoalveolar
lavage (BAL) cultures has been shown as a reliable
method for in evaluating CF pathogens in comparison to
nasopharyngeal cultures as well as identifying anaerobes in
the younger population as compared to older population
who have a less diverse microbiota (15-17).
Several studies have shown BAL culture from the most
damaged lobe represented all the organisms as seen in
the rest of the lung and that there is increased diversity
in protected brush sampling as compared to BAL (16,17).
Sputum cultures have been beneficial in identifying
numerous bacteria but it does not reflect the entire diversity
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of the microbiome in the lower airways as compared to
samples obtained by BAL or protected brush sample (15).
With the increasing identification of diversity and bacterial
burden noted on molecular based studies, there seems to be no
increased bacterial burden in pulmonary exacerbations (17).
Henig et al. had looked at the airways of adult CF patients
by sampling sputum induction using hypertonic saline,
expectorated sputum and BAL with fiberoptic bronchoscope.
The results showed that samples obtained by sputum
induction had advantages including less quantity of squamous
cells, marginally better microbiological results compared
to BAL specimens, and similar quantities of inflammatory
mediators. Each sampling techniques revealed similar
characteristics that was predominant in the airways (18).
Early identification of organisms, especially Pseudomonas
aeruginosa, is important in the early eradication of
Pseudomonas aeruginosa to prevent chronic infections
and to identify other lower respiratory organisms to
target appropriate antibiotics which is not easily identified
with oral pharyngeal swabs and in those who cannot
expectorate. Aaron et al. had looked at the presence of
biofilm-forming Pseudomonas aeruginosa and whether
the strains differ between sputum collection or protected
brush specimens and BAL using fiberoptic bronchoscopy.
Both BAL and protected brushings were not superior to
sputum specimens for identifying the different strains
of Pseudomonas aeruginosa and the differences in the
antibiotic susceptibility. It was also shown that the sputum
samples showed a better representation of the Pseudomonas
aeruginosa strains since the sputum samples represented not
only from distal airways from the upper airways as well as
compared to BAL samples (19).
Jain et al. reviewed that there was no benefit in
bronchoscopy guided therapy compared to standard therapy
which included sputum, throat swab, and cough swab on
FEV1 and FVC and BMI in children. There were also
increased hospital admissions in the BAL directed treatment
but with shorter duration of stay. However, there was no
significant reduction in the health care cost between the two
groups (20). Wainwright et al. have shown that BAL directed
therapy provided no benefit in regards to preventing
structural changes on radiological imaging or reducing
Pseudomonas aeruginosa infection in children. However,
there were adverse events related to bronchoscopy with
BAL which included clinical deterioration within 24 hours
of BAL (4.8%), readmission post procedure (2.3%),
contaminated bronchoscope (0.4%), fever greater than
38.5 degree Celsius (7.6%), and transient worsening of
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cough post procedure (29%) (20).
NTM are increasingly prevalent in CF as the CF
population continues to age with the fact that there is an
increase in organism load with advancing age. Studies
have shown patients with non-tuberculous mycobacteria
were older, have mild pulmonary disease, and often with
Staphylococcus aureus in the sputum cultures (21-23).
Isolating NTM is a challenge and often question whether the
presence of NTM pose as a colonizer or cause for infection
in the lungs (24). The combination of clinical evidence,
radiological findings, and positive cultures including
sputum and bronchial washings with non-tuberculous
mycobacteria is essential for the diagnosis of non-tuberculous
mycobacterial lung disease but it becomes a challenge in CF
where identical symptoms have been associated with other
pathogens (10,25). Tomashefski et al. had looked at the
autopsies of CF patients who had positive sputum cultures
for non-tuberculous mycobacteria and demonstrated
only a small portion of patients with histological evidence
of the disease (26). Tanaka et al. had demonstrated
combination of computed tomography findings suggestive
of Mycobacterium avium complex (MAC) along with
positive bronchial washings for MAC and biopsies
revealing granulomas indicated invasive disease rather than
colonization in non CF patients (27). It is recommended
that in CF patients who have positive cultures for NTM
with clinical deterioration including pulmonary function
and have excluded other conditions should be evaluated
for NTM treatment (28-31). Bronchoscopy with BAL and
transbronchial biopsies can be considered if there is a strong
indication for evaluating and treating NTM.
Role of bronchoscopy in noninfectious causes in
CF
Although there were studies to show the usefulness
of bronchoscopy with endobronchial biopsies help to
understand airway remodeling and to decelerate the
progressive airway damage in children, hemoptysis has been
noted more frequently in older CF patients with progressive
lung disease associated with Pseudomonas aeruginosa,
Burkholderia cepacia, and Staphylococcus aureus along with
persistent airway inflammation and angiogenesis of bronchial
arteries which are bordering to the airways (32-34).
Endobronchial biopsies have been useful in understanding
airway remodeling and inflammatory changes in early CF
disease including in those who are asymptomatic (33).
Despite the detailed understanding of airway remodeling,
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sampling has been limited to mostly in the proximal larger
airways, smaller areas sampled, and lesser thickness of the
airways as supposed to full thickness of the airways (34).
Airway inflammation has been demonstrated in infants
especially in those with negative cultures for the common
bacterial and viral pathogens. Other changes noted include
increase in airway smooth muscle cells which could play
a role in airway hyper-responsiveness and destruction
with fibrotic changes to cartilage which can lead to
tracheomalacia and bronchomalacia seen in advanced
CF disease (34-38). Reticular basement membrane
thickening which has been demonstrated as part of airway
remodeling in CF safe guards the airways by limiting
proteolytic enzymes released from neutrophilic infiltration
to the subepithelial space thus slowing down airway
narrowing. As the disease progresses, the reticular basement
membranes start to thin causing further inflammation of the
airways (33). Vascular changes causing increased blood flow
has been seen which is thought to be related to endothelial
dysfunction potentiating vasoconstrictor pathways (34,39).
Lobar atelectasis has been reported up to 11% of
CF patients (40,41). This is due various factors such
as progression of disease, allergic bronchopulmonary
aspergillosis, factors that would further alter the viscosity
of sputum such as hyperglycemia and hemoptysis.
Bronchoscopy with instillation of recombinant human
DNase as single or sequential therapies have been
reported after failure of standard of treatment including
intravenous antibiotics, intermittent positive pressure
breathing, and airway clearance therapy (42-46). Figure 1
shows a computed tomography image of patient with CF
demonstrating progressive right lung atelectasis.
Plastic bronchitis has also been reported in CF. Though
it is rare, this is caused by acellular bronchial mucus casts
made with mucin. One of the possibilities that cause
plastic bronchitis is lymphatic drainage into the bronchus.
Mechanical removal may be required with foreign body
forceps (47,48).
Tracheomalacia has been associated in children with CF
especially in severe disease. The prevalence in children with
CF is about 15% as compared to 1:2,100 rate estimated
in the general pediatric population. It is more common in
adults with CF with prevalence of 69%. Some of the factors
that have been associated with tracheomalacia include
(I) severe CFTR function leading to severe reduction in
FEV1 developing secondary tracheomalacia due to airway
infection, (II) abnormalities of the tracheal development
predisposing to collapse, (III) combination of congenital

jtd.amegroups.com

J Thorac Dis 2017;9(Suppl 10):S1139-S1145

Journal of Thoracic Disease, Vol 9, Suppl 10 September 2017

S1143

Acknowledgements
None.
Footnote
Conflicts of Interest: The author has no conflicts of interest to
declare.
References
1.

Figure 1 Computed tomography axial image showing progressive
right lung atelectasis due to cystic fibrosis.

tracheomalacia with airway obstruction and infection.
Apart from spirometry and computed tomography of
the chest, flexible bronchoscopy is done to evaluate for
dynamic airway collapse. Positive pressure ventilation can
help improve respiratory symptoms by splinting open the
airways. Pseudomonas aeruginosa has been linked with
early and recurrent infections in children with CF and
tracheomalacia. Other medical therapies that have been
used include mucolytic therapy and Huff-cough. Placement
of biodegradable airway stent to manage localized segments
of tracheomalacia has been done (38,49-51).
Bronchoscopy is used for several reasons in CF most
often for cultures directed for therapy but is used less
often in the advent of similar microbiota seen in induced
sputum. BAL has been considered ideal in obtaining
cultures especially in those who are unable to expectorate.
Now with routine monitoring of surveillance cultures done
as outpatient in CF centers and analyzing the microbiota
of the CF patients including the use of molecular
studies, BAL cultures and protect brush sampling is
almost as equivalent to sputum induction with better
tolerance and less adverse events in sputum induction.
Bronchial washings and transbronchial biopsies are still
considered in evaluating NTM disease if there is a strong
indication. There is utility in performing bronchoscopy
for noninfectious reasons such as lobar collapse and
tracheomalacia as this may be underdiagnosed due to the
progressive nature of CF.

© Journal of Thoracic Disease. All rights reserved.

Cystic fibrosis Foundation. CF Patient Registry 2015 Annual
Data Report. Cystic fibrosis Foundation, Bethesda, Maryland.
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and
management of pulmonary infections in cystic fibrosis. Am
J Respir Crit Care Med 2003;168:918-51.
3. Rafeeq MM, Hussam AS. Cystic fibrosis: current
therapeutic targets and future approaches. Journal of
Translational Medicine 2017;15:84.
4. Morris A, Beck JM, Schloss PD, et al. Lung HIV
Microbiome Project. Comparison of the respiratory
microbiome in healthy nonsmokers and smokers. Am J
Respir Crit Care Med 2013;187:1067-75.
5. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human
DNase I reduces the viscosity of cystic fibrosis sputum.
Proc Natl Acad Sci USA 1990;87:9188-92.
6. McDonald DM. Angiogenesis and remodeling of airway
vasculature in chronic inflammation. Am J Respir Crit
Care Med 2001;164:S39-45.
7. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic
fibrosis airway microbiota is stable over time and infection
type, and highly resilient to antibiotic treatment of
exacerbations. PLoS One 2012;7:e45001.
8. Jung A, Kleinau I, Schonian G, et al. Sequential
genotyping of Pseudomonas aeruginosa from upper and
lower airways of cystic fibrosis patients. Eur Respir J
2002;20:1457-63.
9. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway
inflammation in infants and young children with cystic
fibrosis. Am J Respir Crit Care Med 1997;156:1197-204.
10. Olivier KN, Weber DJ, Wallace RJ Jr, et al.
Non-tuberculous mycobacteria. I: multicenter prevalence
study in cystic fibrosis. Am J Respir Crit Care Med
2003;167:828-34.
11. Gutierrez JP, Grimwood K, Armstrong DS, et al.
Interlobar differences in bronchoalveolar lavage fluid from
children with cystic fibrosis. Eur Respir J 2001;17:281-6.

jtd.amegroups.com

J Thorac Dis 2017;9(Suppl 10):S1139-S1145

S1144

12. Smith DL, Smith EG, Pitt TL, et al. Regional
microbiology of the cystic fibrosis lung: a post-mortem
study in adults. J Infect 1998;37:41-3.
13. Angrill J, Agusti C, de Celis R, et al. Bacterial colonization
in patients with bronchiectasis: microbiological pattern
and risk factors. Thorax 2002;57:15-9.
14. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation
in children with cystic fibrosis and healthy children
assessed by sputum induction. Am J Respir Crit Care Med
2001;164:1425-31.
15. Laguna TA, Wagner BD, Williams CB, et al. Airway
Microbiota in Bronchoalveolar Lavage Fluid from
Clinically Well Infants with Cystic Fibrosis. PLoS One
2016;11:e0167649.
16. Hogan DA, Willger SD, Dolben EL, et al. Analysis of lung
microbiota in bronchoalveolar lavage, protected brush
and sputum samples from subjects with mild-to-moderate
cystic fibrosis lung disease. PLoS One 2016;11:e0149998.
17. Huang YJ, LiPuma JJ. The Microbiome in Cystic Fibrosis.
Clin Chest Med 2016;37:59-67.
18. Henig NR, Tonelli MR, Pier MV, et al. Sputum induction
as a research tool for sampling the airways of subjects with
cystic fibrosis. Thorax 2001;56:306-11.
19. Aaron SD, Kottachchi D, Ferris WJ, et al. Sputum versus
bronchoscopy for diagnosis of Pseudomonas aeruginosa
biofilms in cystic fibrosis. Eur Respir J 2004;24:631-7.
20. Jain K, Wainwright C, Smyth AR. Bronchoscopyguided antimicrobial therapy for cystic fibrosis. Cochrane
Database Syst Rev 2013;12:CD009530.
21. Hjelte L, Petrini B, Kallenius G, et al. Prospective study
of mycobacterial infections in patients with cystic fibrosis.
Thorax 1990;45:397-400.
22. Torrens JK, Dawkins P, Conway SP, et al. Non-tuberculous
mycobacteria in CF. Thorax 1998;53:182-5.
23. Olivier KN, Handler AJ, Lee JH, et al. Clinical impact
of non-tuberculous mycobacteria on the course of CF
lung disease: results of a multicenter, nested cohort study.
Pediatr Pulm 2000;30:102-3.
24. Cullen AR, Cannon CL, Mark EJ, et al. Mycobacterium
abscessus infection in CF. Am J Respir Crit Care Med
2000;161:641-5.
25. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An
official ATS/IDSA statement: diagnosis, treatment, and
prevention of nontuberculous mycobacterial diseases. Am
J Respir Crit Care Med 2007;175:367-416.
26. Tomashefski JF Jr, Stern RC, Demko CA, et al.
Nontuberculous mycobacteria in cystic fibrosis. An autopsy
study. Am J Respir Crit Care Med 1996;154:523-8.

© Journal of Thoracic Disease. All rights reserved.

Paul. Clinical use of bronchoscopy in cystic fibrosis

27. Tanaka E, Amitani R, Nimi A, et al. Yield of computed
tomography and bronchoscopy for the diagnosis of
Mycobacterium avium complex pulmonary disease. Am J
Respir Crit Care Med 1997;155:2041-6.
28. Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic
Mycobacterium abscessus infection and lung function
decline in cystic fibrosis. J Cyst Fibros 2010;9:117-23.
29. Olivier KN, Weber DJ, Lee J-H, et al. for the Nontuberculous Mycobacteria in Cystic fibrosis Study Group.
Non-tuberculous mycobacteria. II: Nested-cohort study
of impact on cystic fibrosis lung disease. Am J Respir Crit
Care Med 2003;167:835-40.
30. Martiniano SL, Nick JA. Non-tuberculous mycobacterial
infections in cystic fibrosis. Clin Chest Med 2015;36:101-15.
31. Ebert DL, Olivier KN. Non-tuberculous mycobacteria in the
setting of cystic fibrosis. Clin Chest Med 2002;23:655-63.
32. Flume PA, Yankaskas JR, Ebeling M, et al. Massive
hemoptysis in cystic fibrosis. Chest 2005;128:729-38.
33. Cohen-Cymberknoh M, Kerem E, Ferkol T, et al. Airway
inflammation in cystic fibrosis: molecular mechanisms and
clinical implications. Thorax 2013;68:1157-62.
34. Regamey N, Jeffery PK, Alton E, et al. Airway remodeling
and its relationship to inflammation in cystic fibrosis.
Thorax 2011;66:624-9.
35. Tiddens HA, Koopman LP, Lambert RK, et al.
Cartilaginous airway wall dimensions and airway resistance
in cystic fibrosis lungs. Eur Respir J 2000;15:735-42.
36. Ogrinc G, Kampalath B, Tomashefski JF Jr. Destruction
and loss of bronchial cartilage in cystic fibrosis. Hum
Pathol 1998;29:65-73.
37. Regamey N, Ochs M, Hilliard TN, et al. Increased airway
smooth muscle mass in children with asthma, cystic
fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir
Crit Care Med 2008;177:837-43.
38. McDermott S, Barry SC, Judge EP, et al. Tracheomalacia
in adults with cystic fibrosis: determination of prevalence
and severity with dynamic cine CT. Radiology
2009;252:577-86.
39. Henno P, Maurey C, Danel C, et al. Pulmonary vascular
dysfunction in end-stage cystic fibrosis: role of NF-kB and
endothelin-1. Eur Respir J 2009;34:1329-37.
40. Di Sant'Agnese PA. Bronchial obstruction with lobar
atelectasis and emphysema in cystic fibrosis of the
pancreas. Pediatrics 1953;12:178-90.
41. Stern RC, Boat TF, Orenstein DM, et al. Treatment and
prognosis of lobar and segmental atelectasis in cystic
fibrosis Am Rev Respir Dis 1978;118:821-6.
42. Flight WG, Hildage J, Kevin Webb A. Progressive

jtd.amegroups.com

J Thorac Dis 2017;9(Suppl 10):S1139-S1145

Journal of Thoracic Disease, Vol 9, Suppl 10 September 2017

43.
44.

45.

46.

47.

unilateral lung collapse in cystic fibrosis--a therapeutic
challenge. J R Soc Med 2012;105 Suppl 2:S44-9.
Nagakumar P, Hilliard T. Recurrent lobar atelectasis in a child
with cystic fibrosis. J R Soc Med 2012;105 Suppl 2:S50-2.
Whitaker P, Brownlee K, Lee T, et al. Sequential
bronchoscopy in the management of lobar atelectasis
secondary to allergic bronchopulmonary aspergillosis. J
Bronchology Interv Pulmonol 2011;18:57-60.
Shah PL, Scott SF, Hodson ME. Lobar atelectasis in cystic
fibrosis and treatment with recombinant human DNase I
Respir Med 1994;88:313-5.
Slattery DM, Waltz DA, Denham B, et al.
Bronchoscopically administered recombinant human
DNase for lobar atelectasis in cystic fibrosis Pediatr
Pulmonol 2001;31:383-8.
Seear M, Hui H, Magee F. Bronchial casts in children: a

S1145

proposed classification based on nine cases and a review of
the literature. Am J Respir Crit Care Med 1997;155:364-70.
48. Salamone I, Mondello B, Lucanto MC, et al. Bronchial
tree-shaped mucous plug in cystic fibrosis: imaging-guided
management. Respirol Case Rep 2017;5:e00214.
49. Fischer AJ, Sachinkumar SB, Adam RJ, et al.
Tracheomalacia is associated with lower FEV1 and
Pseudomonas acquisition in children with CF. Pediatr
Pulmonol 2014;49:960-70.
50. Boogaard R, Huijsmans SH, Pijnenburg MW, et al.
Tracheomalacia and bronchomalacia in children: incidence
and patient characteristics. Chest 2005;128:3391-7.
51. Zopf DA, Hollister SJ, Nelson ME, et al. Bioresorbable
airway splint created with a three-dimensional printer.
N Engl J Med 2013;368:2043-5.

Cite this article as: Paul L. Is bronchoscopy an obsolete tool
in cystic fibrosis? The role of bronchoscopy in cystic fibrosis
and its clinical use. J Thorac Dis 2017;9(Suppl 10):S1139S1145. doi: 10.21037/jtd.2017.06.143

© Journal of Thoracic Disease. All rights reserved.

jtd.amegroups.com

J Thorac Dis 2017;9(Suppl 10):S1139-S1145

